Concurrent use may increase toxicity of flucytosine by increasing cellular uptake and/or impairing renal excretion.
Source: NLP:amphotericin b
Flucytosine Interactions
Brand names: Flucytosine
Nucleoside Analog Antifungal
Route: Oral
FDA Black Box Warning
WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of Flucytosine Capsules USP.
Contraindications
CONTRAINDICATIONS Flucytosine Capsules, USP is contraindicated in patients with a known hypersensitivity to the drug. Flucytosine Capsules, USP is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (see WARNINGS ).
Pregnancy & Breastfeeding
Pregnancy Teratogenic Effects Flucytosine was shown to be teratogenic (vertebral fusions) in the rat at doses of 40 mg/kg/day (298 mg/M 2 /day or 0.051 times the human dose) administered on days 7 to 13 of gestation. At higher doses (700 mg/kg/day; 5208 mg/M 2 /day or 0.89 times the human dose administered on days 9 to 12 of gestation), cleft lip and palate and micrognathia were reported. Flucytosine was not teratogenic in rabbits up to a dose of 100 mg/kg/day (1423 mg/M 2 /day or 0.243 times the human dose) administered on days 6 to 18 of gestation. In mice, 400 mg/kg/day of flucytosine (1380 mg/M 2 /day or 0.236 times the human dose) administered on days 7 to 13 of gestation was associated with a low incidence of cleft palate that was not statistically significant. Studies in pregnant rats have shown that flucytosine injected intraperitoneally crosses the placental barrier. There are no adequate and well-controlled studies in pregnant women. Flucytosine Capsules USP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
9 interactions on record
Cytosine arabinoside inactivates the antifungal activity of flucytosine through competitive inhibition.
Source: NLP:flucytosine
Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits outweigh risks.
Source: NLP:ganciclovir sodium
Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential for higher toxicity from myelosuppression or nephrotoxicity.
Source: NLP:valganciclovir hydrochloride
Drugs that impair glomerular filtration may prolong the biological half-life of flucytosine.
Source: NLP:flucytosine
Flucytosine + GanciclovirModerate
Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.
Source: NLP:ganciclovir
Flucytosine + ValganciclovirModerate
Drug associated with myelosuppression or nephrotoxicity. Consider coadministration only if potential benefits outweigh risks.
Source: NLP:valganciclovir
Synergism or antagonism between clotrimazole and flucytosine has not been reported.
Source: NLP:clotrimazole topical
Flucytosine + CotrimoxazoleUnknown
Synergism or antagonism between clotrimazole and flucytosine against C. albicans has not been reported.
Source: NLP:clotrimazole